Testing immunotherapy with or without targeted radiation for melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether combining two immunotherapy medicines (ipilimumab and nivolumab) works better with targeted radiation for metastatic melanoma that has specific treatable spots. It may help shrink tumors and improve control of the disease, depending on your individual situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread (metastatic), confirmed by pathology/biopsy
- You have at least two measurable tumor spots that can be tracked on scans
- You have one main tumor spot between 1 and 7 cm that a radiation doctor can treat with a shorter radiation schedule
- You can safely do the radiation planning and treatment positions (you can lie flat and hold still)
- Your overall condition is fairly good (ECOG performance status 0–1)
- Your recent body tests (blood counts, kidney, liver) are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.